ArticleProceedings of the National Academy of Sciences of the United States of America1995
Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 73 citations in OpenAlex.
- Trial
- A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.British journal of cancer · 2007Trial
- Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy.International journal of molecular sciences · 2023Article
- Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.Journal of translational medicine · 2023Article
- PBMC activation via the ERK and STAT signaling pathways enhances the anti-tumor activity of Staphylococcal enterotoxin A.Molecular and cellular biochemistry · 2017Article
- 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Cancer immunology, immunotherapy : CII · 2017Review
- Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.Current oncology reports · 2014Review
- Article
- Solid tumor-targeted infiltrating cytotoxic T lymphocytes retained by a superantigen fusion protein.PloS one · 2011Article
- Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth.Cancer gene therapy · 2008Article
- Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene.Cancer science · 2004Article
- In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein.Cancer immunology, immunotherapy : CII · 2004Article
- Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.British journal of cancer · 2001Article
- Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.Gene therapy · 2001Article
- The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.British journal of cancer · 1999Article
- Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.Clinical and diagnostic laboratory immunology · 1998Article
- Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.The American journal of pathology · 1997Article
- Genetically engineered superantigens as tolerable antitumor agents.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.Immunology · 1997Article
- Genetically engineered superantigens in experimental tumor therapy.Springer seminars in immunopathology · 1996Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recruitment of antigen-specific tumor-infiltrating lymphocytes (TILs) is a major goal for immunotherapy of malignant tumours. We now describe that T-cell-activating superantigens targeted to a tumor by monoclonal antibodies induced large numbers of pseudospecific TILs and eradication of micrometastases. As a model for tumor micrometastases, syngeneic B16 melanoma cells transfected with the human colon carcinoma antigen C215 were injected intravenously into C57BL/6 mice and therapy with an anti-C215 Fab fragment-staphylococcal enterotoxin A (C215Fab-SEA) fusion protein reacting with the C215 antigen was initiated when visible lung metastases were established. More than 90% reduction of the number of lung metastases was observed when mice carrying 5-day-old established lung metastases were treated with C215Fab-SEA. The antitumor effect of C215Fab-SEA was shown to be T-cell-dependent since no therapeutic effect was seen in T-cell-deficient nude mice. Depletion of T-cell subsets by injection of monoclonal antibody demonstrated that CD8+ cells were the most prominent effector cells although some contribution from CD4+ cells was also noted. C215Fab-SEA treatment induced massive tumor infiltration of CD4+ and CD8+ T cells, while only scattered T cells were observed in untreated tumors. SEA treatment alone induced a slight general inflammatory response in the lung parenchyme, but no specific accumulation of T cells was seen in the tumor. TILs induced by C215Fab-SEA were mainly CD8+ but a substantial number of CD4+ cells were also present. Immunohistochemical analysis showed strong production of the tumoricidal cytokines tumor necrosis factor alpha and interferon gamma in the tumor. Thus, the C215Fab-SEA fusion protein targets effector T lymphocytes to established tumors in vivo and provokes a strong local antitumor immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.